In multiple preclinical cancer models including AML, TIGIT expression was strongly associated with expression of other co-inhibitory molecules such as PD-1, Tim-3 and Lag-3, indicating the potential need for targeting multiple checkpoints in AML treatment [44, 45]. The gene discussed is LAG3; the disease is cancer.